Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$14.15
-2.1%
$16.55
$3.25
$21.48
$378.83M1.18258,292 shs135,475 shs
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$8.53
-2.4%
$8.99
$5.04
$15.36
$426.11M1.06927,669 shs220,144 shs
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
$16.31
-0.7%
$16.81
$11.56
$29.79
$418.71M2314,508 shs41,285 shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.38
-10.1%
$0.47
$0.29
$1.07
$89.50M1.142.47 million shs2.60 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
0.00%+3.68%-13.75%+22.57%+337.50%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
0.00%+4.05%-9.16%+47.22%-19.91%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
0.00%+1.42%-12.95%+32.92%+33.88%
Vaxart, Inc. stock logo
VXRT
Vaxart
0.00%-12.64%+6.59%+38.86%-34.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
2.7236 of 5 stars
3.53.00.00.02.11.70.6
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
4.4872 of 5 stars
3.43.00.04.62.13.30.6
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
2.1135 of 5 stars
3.53.00.00.00.62.50.0
Vaxart, Inc. stock logo
VXRT
Vaxart
2.2594 of 5 stars
3.51.00.00.02.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
3.00
Buy$29.67108.95% Upside
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
2.83
Moderate Buy$31.63273.82% Upside
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
3.00
Buy$49.33207.18% Upside
Vaxart, Inc. stock logo
VXRT
Vaxart
3.00
Buy$3.00644.42% Upside

Current Analyst Ratings Breakdown

Latest VXRT, RGNX, TRML, and ETON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$52.00
5/29/2025
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $35.00
5/16/2025
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $26.00
5/14/2025
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$26.00 ➝ $28.00
5/5/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
5/5/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
4/23/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$70.00
4/17/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$39.01M9.76N/AN/A$0.94 per share15.10
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$83.33M5.09N/AN/A$5.24 per share1.61
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/A$11.71 per shareN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
$28.70M3.21N/AN/A$0.26 per share1.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
-$3.82M-$0.18N/A28.40N/A-9.49%-3.15%-1.08%8/4/2025 (Estimated)
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$227.10M-$3.11N/AN/AN/A-100.62%-53.29%-30.84%8/7/2025 (Estimated)
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$73.21M-$3.21N/AN/AN/AN/A-26.75%-26.11%8/6/2025 (Estimated)
Vaxart, Inc. stock logo
VXRT
Vaxart
-$66.95M-$0.27N/AN/AN/A-122.63%-91.89%-38.40%8/14/2025 (Estimated)

Latest VXRT, RGNX, TRML, and ETON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$0.09$0.07-$0.02-$0.06$14.33 million$17.28 million
5/13/2025Q1 2025
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.07-$0.07N/A-$0.07$2.85 million$20.88 million
5/12/2025Q1 2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$0.41$0.12-$0.29$0.12$105.35 million$89.01 million
5/2/2025Q1 2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$0.91-$0.89+$0.02-$0.89N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
N/AN/AN/AN/AN/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/AN/AN/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
1.23
1.97
1.43
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/A
2.93
2.93
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/A
33.87
33.87
Vaxart, Inc. stock logo
VXRT
Vaxart
N/A
0.64
0.64

Institutional Ownership

CompanyInstitutional Ownership
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
27.86%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
88.08%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
91.89%
Vaxart, Inc. stock logo
VXRT
Vaxart
18.05%

Insider Ownership

CompanyInsider Ownership
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
14.89%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
12.79%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
13.00%
Vaxart, Inc. stock logo
VXRT
Vaxart
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
2026.82 million22.83 millionOptionable
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
37050.16 million43.75 millionOptionable
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
4425.68 million22.35 millionOptionable
Vaxart, Inc. stock logo
VXRT
Vaxart
120228.31 million222.37 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Eton Pharmaceuticals stock logo

Eton Pharmaceuticals NASDAQ:ETON

$14.15 -0.30 (-2.10%)
As of 01:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

REGENXBIO stock logo

REGENXBIO NASDAQ:RGNX

$8.53 -0.21 (-2.40%)
As of 01:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Tourmaline Bio stock logo

Tourmaline Bio NASDAQ:TRML

$16.30 -0.12 (-0.70%)
As of 01:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Vaxart stock logo

Vaxart NASDAQ:VXRT

$0.38 -0.04 (-10.07%)
As of 01:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.